12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xtandi enzalutamide regulatory update

Astellas and Medivation said Health Canada approved Xtandi enzalutamide to treat metastatic castration-resistant prostate cancer (CRPC) in patients who have previously received docetaxel therapy. FDA approved the oral androgen...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >